Serum MicroRNA-146a-5p and MicroRNA-221-3p As Potential Clinical Biomarkers for Papillary Thyroid Carcinoma

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2024 Sep 19

PMID 39298113

Authors

Antonella Verrienti

Valeria Pecce

Giorgio Grani

Valeria Del Gatto

Samuele Barp

Marianna Maranghi

Laura Giacomelli

Cira Di Gioia

Marco Biffoni

Sebastiano Filetti

Cosimo Durante

Marialuisa Sponziello

Affiliations

Soon will be listed here.

Abstract

Purpose: Papillary thyroid carcinoma (PTC) is the most common malignant thyroid neoplasm, accounting for approximately 85% of all follicular cell-derived thyroid nodules. This study aimed to assess the diagnostic potential of circulating microRNA-146a-5p and microRNA-221-3p as biomarkers for PTC and their usefulness in monitoring disease progression during patient follow-up.

Methods: An observational study was conducted on two cohorts of PTC patients and healthy controls (HCs) using digital PCR. We collected patients' clinical, biochemical, and imaging data during the post-surgery surveillance. We analyzed the levels of circulating miRNAs in serum samples of patients before surgery and during the follow-up, including those with indeterminate/biochemical incomplete response (IndR/BIR) and residual thyroid tissues (Thy Residue).

Results: Both miR-146a-5p and miR-221-3p were confirmed as effective biomarkers for PTC diagnosis. They enabled differentiation between pre-surgery PTC patients and HCs with an area under the curve (AUC) of 92% and 87.3%, respectively, using a threshold level of 768,545 copies/uL for miR-146a-5p and 389,331 copies/uL for miR-221-3p. It was found that miRNA fold change levels, rather than absolute levels, can be useful during patient follow-up. In particular, we found that a fold change of 2 for miR-146a-5p and 2.2 for miR-221-3p can identify a progressive disease, regardless of the presence of TgAbs or remnant thyroid.

Conclusion: MiRNA-146a-5p and miRNA-221-3p, particularly the former, could be valuable diagnostic biomarkers for PTCs. They also seem to be effective in monitoring disease progression during patient follow-up by evaluating their fold change, even when thyroglobulin is uninformative.

References

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Grani G, Sponziello M, Filetti S, Durante C . Molecular analysis of fine-needle aspiration cytology in thyroid disease: where are we?. Curr Opin Otolaryngol Head Neck Surg. 2021; 29(2):107-112. DOI: 10.1097/MOO.0000000000000698. View

Zhang A, Wang C, Lu H, Chen X, Ba Y, Zhang C . Altered Serum MicroRNA Profile May Serve as an Auxiliary Tool for Discriminating Aggressive Thyroid Carcinoma from Nonaggressive Thyroid Cancer and Benign Thyroid Nodules. Dis Markers. 2019; 2019:3717683. PMC: 6766139. DOI: 10.1155/2019/3717683. View

Indrasena B . Use of thyroglobulin as a tumour marker. World J Biol Chem. 2017; 8(1):81-85. PMC: 5329716. DOI: 10.4331/wjbc.v8.i1.81. View

Lamartina L, Grani G, Durante C, Borget I, Filetti S, Schlumberger M . Follow-up of differentiated thyroid cancer - what should (and what should not) be done. Nat Rev Endocrinol. 2018; 14(9):538-551. DOI: 10.1038/s41574-018-0068-3. View

Chen Y, Dong B, Huang L, Huang H . Serum microRNAs as biomarkers for the diagnosis of papillary thyroid carcinoma: a meta-analysis. Bosn J Basic Med Sci. 2022; 22(6):862-871. PMC: 9589316. DOI: 10.17305/bjbms.2022.7343. View

Verrienti A, Carbone A, Cito D, Sponziello M, Pecce V, Bruno R . Long-term disease recurrence in the adipose tissue and striated muscles of a minimally invasive papillary thyroid carcinoma. Endocrine. 2020; 72(3):937-939. DOI: 10.1007/s12020-020-02558-0. View

Lam A . Papillary Thyroid Carcinoma: Current Position in Epidemiology, Genomics, and Classification. Methods Mol Biol. 2022; 2534:1-15. DOI: 10.1007/978-1-0716-2505-7_1. View

Suarez B, Sole C, Marquez M, Nanetti F, Lawrie C . Circulating MicroRNAs as Cancer Biomarkers in Liquid Biopsies. Adv Exp Med Biol. 2022; 1385:23-73. DOI: 10.1007/978-3-031-08356-3_2. View

Verrienti A, Pecce V, Abballe L, Ramundo V, Falcone R, Inanloo Nigi Jak F . Analytical validation of a novel targeted next-generation sequencing assay for mutation detection in thyroid nodule aspirates and tissue. Endocrine. 2020; 69(2):451-455. DOI: 10.1007/s12020-020-02372-8. View

10.

Zhang Y, Xu D, Pan J, Yang Z, Chen M, Han J . Dynamic monitoring of circulating microRNAs as a predictive biomarker for the diagnosis and recurrence of papillary thyroid carcinoma. Oncol Lett. 2017; 13(6):4252-4266. PMC: 5452941. DOI: 10.3892/ol.2017.6028. View

11.

Besharat Z, Trocchianesi S, Verrienti A, Ciampi R, Cantara S, Romei C . Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients. J Endocrinol Invest. 2023; 46(12):2583-2599. PMC: 10632281. DOI: 10.1007/s40618-023-02115-2. View

12.

Haugen B, Alexander E, Bible K, Doherty G, Mandel S, Nikiforov Y . 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015; 26(1):1-133. PMC: 4739132. DOI: 10.1089/thy.2015.0020. View

13.

Capriglione F, Verrienti A, Celano M, Maggisano V, Sponziello M, Pecce V . Analysis of serum microRNA in exosomal vehicles of papillary thyroid cancer. Endocrine. 2021; 75(1):185-193. DOI: 10.1007/s12020-021-02847-2. View

14.

Lin E . Radiation risk from medical imaging. Mayo Clin Proc. 2010; 85(12):1142-6. PMC: 2996147. DOI: 10.4065/mcp.2010.0260. View

15.

Celano M, Rosignolo F, Maggisano V, Pecce V, Iannone M, Russo D . MicroRNAs as Biomarkers in Thyroid Carcinoma. Int J Genomics. 2017; 2017:6496570. PMC: 5606057. DOI: 10.1155/2017/6496570. View

16.

Sponziello M, Brunelli C, Verrienti A, Grani G, Pecce V, Abballe L . Performance of a dual-component molecular assay in cytologically indeterminate thyroid nodules. Endocrine. 2020; 68(2):458-465. DOI: 10.1007/s12020-020-02271-y. View

17.

Kobaly K, Kim C, Mandel S . Contemporary Management of Thyroid Nodules. Annu Rev Med. 2021; 73:517-528. DOI: 10.1146/annurev-med-042220-015032. View

18.

Campenni A, Aguennouz M, Siracusa M, Alibrandi A, Polito F, Oteri R . Thyroid Cancer Persistence in Patients with Unreliable Thyroglobulin Measurement: Circulating microRNA as Candidate Alternative Biomarkers. Cancers (Basel). 2022; 14(22). PMC: 9688692. DOI: 10.3390/cancers14225620. View

19.

Graham M, Hart R, Douglas S, Makki F, Pinto D, Butler A . Serum microRNA profiling to distinguish papillary thyroid cancer from benign thyroid masses. J Otolaryngol Head Neck Surg. 2015; 44:33. PMC: 4560924. DOI: 10.1186/s40463-015-0083-5. View